Severe sepsis is described as a complex clinical syndrome resulting from overreaction of the immune system to infection (6) . Within a period of 21 years, about 10 million cases of severe sepsis occurred in the United States with a threefold increase of cases from 1979 to 2000 (20) . Severe sepsis remains one of the main causes of death in intensive care units in the United States, with an overall mortality of about 30% (1) .
The discovery and characterization of germ line-encoded immune receptors known as the Toll-like receptor (TLR) family have been a milestone in understanding the immunopathogenesis of sepsis (21, 31) . Innate immune receptors sense molecular signatures on invading pathogens and form the first line of defense (18) . All TLRs are type I membrane proteins with characteristic extracellular leucine-rich repeats and highly homologous Toll/interleukin-1 receptor (TIR) cytoplasmic domains (25) . After homo-or heterodimerization, they initiate signaling cascades resulting in activation of transcription of multiple inflammatory genes through NF-B, IRF, or AP-1 pathways (14) .
It has been clearly demonstrated that TLR4 is the mammalian receptor for lipopolysaccharide (LPS) from Enterobacteriaceae (4, 10, 27) . The lethal effects of gram-negative bacterial sepsis are linked, at least in part, to LPS as a major compound of the outer membrane of gram-negative bacteria. Recognition of LPS is dependent on several proteins: LPS binding protein transfers LPS to soluble or cell membrane-anchored CD14 (9) , which in turn transfers LPS to the TLR4/MD-2 complex (7). MD-2 acts as the actual LPS binding component, whereas TLR4 functions as the signaling subunit of the LPS-receptor complex (23) . Recently the structure of the full-length ectodomain of TLR4 and MD-2 and the hydrophobic binding pocket of MD-2 for the LPS antagonist Eritoran was determined by crystal structure analysis (16) . Therefore, it is possible that LPS interacts with TLR4/MD-2 in a similar fashion.
Stimulation of TLR4 during gram-negative bacterial infection can lead to a vast cytokine response, potentially resulting in multiple organ failure. In order to control the overwhelming inflammation, we constructed a FLAG-tagged fusion protein consisting of the extracellular domain of mouse TLR4 linked to mouse MD-2 via a flexible linker (LPS-Trap) (2) . LPS-Trap formed the LPS binding complex of TLR4/MD-2, bound to LPS, and dampened LPS-induced proinflammatory reactions in vitro (2, 33) .
With the intent to extend the features of LPS-Trap, the six-His tag was replaced by human immunoglobulin G (IgG)-Fc fragments. Generally, Fc chimeras of recombinant proteins show the following advantages (3): (i) increase in total avidity for liganding by being bivalent, (ii) the possibility of purification from supernatants by using protein A or G affinity chromatography, (iii) increase in serum half-life, and (iv) activation of effector cells and biological activity. In this work we focused on the biological activity of LPS-Trap-Fc in vitro to investigate whether such constructs would show additional biological activities. We supposed that association with bacterial surfaces would trigger biological effects that support bacterial clearing. Therefore, our aim in the present work was to confirm binding of LPS-Trap to gram-negative bacteria, probably through its mouse MD-2 subunit, and to investigate potential additional beneficial effects of the opsonization which could be of help in by using the ECL Plus Western blot detection reagents (GE Healthcare, Little Chalfont, United Kingdom).
The LPS pulldown assay for determination of LPS binding was originally described in reference 38. In brief, 2 ml of LPS-Trap-Fc1-containing supernatants supplemented with 10% FCS was incubated with 0.5 g/ml biotinylated LPS (Invivogen) for 1 h at room temperature, followed by immunoprecipitation with 25 l streptavidin-Sepharose High Performance (GE Healthcare). For specificity control, some supernatants were preincubated with either 50 g/ml LPS (Salmonella enterica serovar Minnesota; Sigma), which has a high binding activity for TLR4/MD-2, or 10 g/ml anti-mouse TLR4/MD-2 MTS510 MAb (Hycult Biotechnology, Uden, The Netherlands) for 1 h at room temperature. Precipitates were washed three times with PBS plus 0.05% Tween 20 (PBST). Proteins were eluted by boiling the Sepharose in Laemmli buffer and subjected to SDS-PAGE. Bound protein was detected by Western blotting as described above.
Biologic activity of LPS-Trap-Fc. For determination of biologic activity of LPS-Trap-Fc, 5 ϫ 10 4 cells per well of the LPS-responder mouse macrophagelike cell line RAW 264.7 were seeded in 96-well plates (Corning Inc., Corning, NY). After adherence of the cells, LPS-Trap-Fc1 concentrates with final concentrations of 0.6, 1.5, 3, and 6 nM or PBS as control were added to the media. The cells were stimulated with 100 ng/ml ultrapure LPS (Salmonella enterica serovar Abortusequi S form; Alexis Biochemicals, Gruenberg, Germany) overnight in a final volume of 150 l. The supernatants were tested for secreted interleukin-6 (IL-6) by ELISA (Becton Dickinson, Heidelberg, Germany).
LPS-Trap binding to bacteria. LPS-Trap-Fc1 concentrates were added to heat-inactivated (80°C, 10 min) E. cloacae (5 ϫ 10 7 CFU/ml) in PBS plus 10% FCS, incubated for 1 h at 37°C, and washed with PBS plus 10% FCS twice. Bound LPS-Trap-Fc1 was detected by fluorescence-activated cell sorting (FACS) using an anti-FLAG M2-fluorescein isothiocyanate (FITC)-conjugated MAb (Sigma-Aldrich).
For the bacterial ELISA, E. coli, B. subtilis, or E. cloacae bacteria after overnight culture were pelleted and resuspended to an OD 600 of 0.4, which corresponds to about 5 ϫ 10 8 CFU/ml. Bacteria were further diluted to 1 ϫ 10 8 CFU/ml with PBS and adsorbed to Immunolon 2 HB plates (Thermo, Milford, MA) for 2 h at room temperature (1 ϫ 10 7 CFU/well) or in twofold dilutions starting from 2 ϫ 10 7 CFU/well. After being blocked with PBS plus 1% bovine serum albumin, 100 l of LPS-Trap-Fc1-containing supernatants was applied to the wells for 2 h at room temperature. After being washed with PBST three times, LPS-Trap associated with the surface of bacteria was detected with an anti-FLAG M2-HRP-conjugated MAb (Sigma-Aldrich). As a specificity control, LPS-Trap-Fc1-containing supernatants preblocked with 10 g/ml LPS for 1 h at room temperature were used. Supernatants containing recombinant soluble interleukin-1 receptor accessory protein (FLAG-sAcP), which bears an N-terminal FLAG tag and a six-His tag arranged in tandem, served as the negative control.
Phagocytosis assay. Fluorescent E. coli particles (5 ϫ 10 6 /ml; BODIPY FL bioparticles; Invitrogen) were incubated with serum-free LPS-Trap-Fc chimera containing HEK293T cell supernatants or human IgG in Panserin (10 g/ml or 100 g/ml) for 1 h at 37°C (opsonization period). Particles were then centrifuged at 1,000 ϫ g for 15 min and washed three times with PBS. As phagocytes, cells of the human monocytic cell line Mono Mac 6, which resemble human macrophages (13, 39) , were used. Opsonized particles (5 ϫ 10 6 ) were added to 5 ϫ 10 5
Mono Mac 6 cells, in Hanks balanced salt solution (Invitrogen) containing calcium, magnesium, and 0.5% human serum albumin (DRK, Baden-Baden, Germany). To ensure proper exposure of phagocytes to E. coli particles, reaction tubes were centrifuged (500 ϫ g for 5 min at 4°C). Phagocytosis was performed for 10, 20, 30, and 60 min. Cells were then washed once with PBS, and to quantify internalized E. coli particles only, extracellular fluorescence was quenched with 0.05% trypan blue (Biochrom) (28, 32, 34) . Living Mono Mac 6 cells were gated according to their forward and side scatter characteristics. The extent of phagocytosis was quantified as percentage of positive cells in fluorescence channel 1 (FL1, 525 nm, green) and a phagocytosis index. The phagocytosis index was calculated as follows: (geometric mean of fluorescence of gated cells ϫ percentage of positive cells)/100 (28) . Determination of complement activity. The susceptibility of LPS-Trap-Fc1-to -Fc4-treated bacteria to complement lysis was determined by determining CFU. Overnight cultures of E. cloacae were diluted (1:100) in fresh MacConkey growth medium and grown until exponential phase. Bacteria were harvested and resuspended in PBS, LPS-Trap-Fc1 to -Fc4 concentrates (30 nM), a His-tagged LPS-Trap control protein (60 nM), or an Fc-tagged TLR2/TLR6 fusion protein (30 nM, T2/6-Fc) in PBS to a final concentration of 1 ϫ 10 7 CFU/ml and incubated for 1 h at room temperature. After bacteria were washed twice with PBS, complement reactions were carried out in 5 l/ml human complement serum (Sigma-Aldrich) in Hanks balanced salt solution supplemented with 0.5% human serum albumin for 90 min at 37°C without shaking. The reactions were stopped by placing the samples on ice. Bacteria were harvested and resuspended in PBS. Serial dilutions of bacterial suspensions were plated on MacConkey agar plates. After incubation at 37°C, overnight colonies on plates were counted.
The resistance of LPS-Trap-Fc1-to -Fc4-treated E. cloacae to serum bactericidal activity was tested by a turbidimetric assay adapted from previous studies (15, 35) . Bacterial cultures were prepared as described above. Bacteria were harvested and resuspended in PBS, LPS-Trap-Fc1 to -Fc4 concentrates (30 nM), or an Fc-tagged control protein (30 nM, T2/6-Fc) in PBS to a final concentration of 5 ϫ 10 6 CFU/ml. The suspensions were distributed in a 96-well plate together with an equal volume of pooled human sera (75 l each) and incubated at 37°C. Incubation with heat-inactivated serum (56°C, 30 min) served as a control. Bacterial growth was measured by OD 650 .
Statistical analysis. Statistical analysis was performed using Sigma Stat 3.5 (Systat, Erkrath, Germany). Samples were analyzed by the Mann-Whitney U test. Multiple comparisons were done by analysis of variance (ANOVA) and by Holm-Sidak post hoc test. Differences were considered significant for P Ͻ 0.05.
RESULTS
Production of TLR4/MD-2-Fc fusion proteins. The TLR4/ MD-2 fusion protein LPS-Trap was originally designed to capture soluble LPS and hence prevent overwhelming inflammation and septic shock (2) . It consists of the extracellular portion of mouse TLR4 fused with mouse MD-2 via a 15-amino-acid flexible linker. To allow its identification and purification from cell supernatants, it was tagged with an N-terminal FLAG tag and a C-terminal six-His tag (Fig. 1A) . In order to investigate its opsonization capabilities, the His tag was replaced by the various IgG Fc fragments. FLAG-TLR4/MD-2 cDNA was cloned into expression vectors bearing the different human IgG-Fc coding sequences to obtain LPS-Trap-Fc chimeras (LPS-Trap-Fc1, -Fc2, -Fc3, and -Fc4) (Fig. 1A) , and HEK293T cells were transiently transfected. Protein production was tested 48 h after transfection by SDS-PAGE and subsequent Western blotting of cell supernatants. The integrity of the proteins was ensured by using anti-FLAG as well as anti-human-IgG-Fc antibodies under reducing conditions. As expected, the fusion proteins were produced with a molecular mass of 140 kDa in a soluble form and secreted into cell supernatants (Fig. 1B) . The unreduced form had a molecular size of about 280 kDa, and the deglycosylated form had the expected size of 117 kDa (not shown).
LPS-Traps-Fc1 to -Fc4 bind to LPS and are biologically active. To confirm LPS binding, supernatants of HEK293T cells after transfection with LPS-Trap-Fc1 expression plasmids were incubated with biotinylated LPS (biotin-LPS) and the complexes were subsequently precipitated with streptavidinSepharose. The immunoprecipitates were analyzed by SDS-PAGE and immunoblotted with an anti-FLAG MAb ( Fig. 2A) . With biotin-LPS alone, bands corresponding to LPS-Trap-Fc1 to -Fc4 were found ( Fig. 2A, lane 1) . After preincubation of the supernatants with an anti-TLR4/MD-2 MAb which reacts preferentially with TLR4 associated with MD-2 and does not bind TLR4 alone, thus masking the LPS binding pocket, the binding of biotin-LPS to LPS-Trap-Fc1 to -Fc4 was inhibited as shown in Fig. 2A , lane 2. Preincubation of supernatants with an excess of unlabeled LPS also inhibited binding (Fig. 2A, lane  4) . LPS-Trap-Fc2, -Fc3, and -Fc4 fusion proteins showed comparable results (data not shown). Taken together, these findings indicate that the binding of LPS to the four fusion proteins was specific for the LPS binding pocket formed by the TLR4/ MD-2 complex.
In order to test the inhibitory activity of the fusion protein, RAW 264.7 cells were treated with different doses of LPSTrap-Fc1 concentrates and stimulated with 100 ng/ml LPS. LPS-Trap-Fc1-treated RAW 264.7 cells showed a dose-dependent decrease of IL-6 production (Fig. 2B) . This shows that LPS-Trap-Fc can efficiently bind LPS and inhibit LPS-triggered responses in vitro.
LPS-Trap proteins bind specifically to gram-negative bacteria. Given that human MD-2 bound to the surface of gramnegative bacteria (12, 37) and that soluble TLR4-Fc chimeras were still able to associate with MD-2 bound to bacteria (12), we hypothesized that LPS-Trap should bind to bacteria. A representative gram-negative organism, E. cloacae, was treated with different amounts of LPS-Trap-Fc1 concentrates, and LPS-Trap-Fc associated with bacteria was detected with anti-FLAG-FITC MAb by FACS. LPS-Trap-Fc bound to the surface of E. cloacae in a dose-dependent manner (Fig. 3A) . No binding was detected when FLAG-tagged sAcP-treated bacteria were analyzed (Fig. 3A) .
To test binding of LPS-Trap-Fc to live bacteria, wells of ELISA plates were coated with two representatives of enterobacteria, E. coli and E. cloacae, or the gram-positive species Bacillus subtilis as a control. Adherent bacteria were incubated with supernatants containing LPS-Trap-Fc1 or FLAG-sAcP as control, and bound proteins were detected by an anti-FLAG-HRP MAb. Again LPS-Trap-Fc1 showed a robust association with gram-negative bacteria but not with B. subtilis (Fig. 3B) . (Fig. 3B) . Binding was dependent on the number of E. coli bacteria bound to the wells (Fig. 3C) . These results show that LPS-Trap proteins specifically bind gram-negative bacteria and that only the TLR4/MD-2 moiety was required for this activity.
LPS-Traps-Fc1 to -Fc4 modulation of phagocytosis is IgG isotype dependent.
To test whether the Fc chimeras of LPSTrap can be opsonins for gram-negative bacteria, fluorescent E. coli particles were incubated with LPS-Trap-Fc1 concentrates or with 10 g/ml human IgG-containing supernatants, respectively. Mono Mac 6 cells used as phagocytes were incubated for 1 h with opsonized bacteria at a bacteriumto-cell ratio of 10:1. Sodium azide-inactivated Mono Mac 6 cells incubated with nonopsonized E. coli particles served as an additional control for nonspecific adhesion. The LPSTrap-Fc1-opsonized particles led to increased phagocytosis in comparison with human IgG-opsonized particles (Fig. 4A  and B) .
In order to investigate the influence of the different IgG isotypes, the phagocytosis rates of LPS-Traps-Fc1 to -Fc4, LPS-Trap, or human IgG-opsonized E. coli particles were determined. As expected, LPS-Trap-Fc1 and -Fc3 had the strongest effect, whereas LPS-Trap-Fc2 and -Fc4 were comparable to human IgG. LPS-Trap (lacking Fc) alone was much less effective in stimulating phagocytosis (Fig. 4C) . LPS-Traps-Fc1 to -Fc4 modulation of complement activation is dependent on IgG isotype. To measure complement activation, LPS-Trap-Fc1 to -Fc4 concentrates were incubated with E. cloacae and subsequently treated with human complement serum. The number of remaining live bacteria was determined as CFU. Whereas LPS-Trap-Fc1-and -Fc3-opsonized bacteria showed enhanced susceptibility to complement, there was no significant difference among bacteria treated with PBS without complement (PBS w/o), PBS, human IgG1-Fc control protein (T2/6-Fc), LPS-Trap (His), LPS-Trap-Fc2, and LPS-Trap-Fc4 (Fig. 5A) . Moreover, natural resistance of E. cloacae to human serum was abolished by opsonization with LPS-Trap-Fc1 and -Fc3 (Fig. 5B) .
Taken together, these results indicate that the TLR4/MD-2 fusion protein LPS-Trap-Fc not only binds to gram-negative bacteria but can also mediate enhanced phagocytosis and complement activation through its biologically active IgG-Fc1 or IgG-Fc3 tail.
DISCUSSION
The complex pathophysiology of sepsis is still not entirely revealed. TLR4 and MD-2 seem to play a key role in the pathogenesis of sepsis, since many symptoms can be evoked by small doses of LPS in humans (36) , though formal proof of this association is lacking. Several studies were undertaken to neutralize the effects of LPS (26, 30) . Modulation of TLR signaling with soluble TLRs might be a useful approach to control TLRinduced hyperinflammation (11, 17, 22) . We tried to modulate TLR4 signaling by using a soluble LPS receptor (2) .
The TLR4/MD-2 fusion protein LPS-Trap-Fc bound LPS via the essential TLR4/MD-2 complex ( Fig. 1 and 2A) , similarly to the monomeric version LPS-Trap (2). LPS-induced cytokine production was also inhibited (Fig. 2B) . Thus, the properties of LPS-Trap-Fc concerning specific binding and neutralization of LPS are comparable with the monomeric Fc-less fusion protein.
Recently it was demonstrated that recombinant human sMD-2 (12, 37) and sMD-2 from human plasma (12) specifically bound to the gram-negative bacterial surface. Our data show also that the preformed TLR4/MD-2 complex-represented by LPS-Trap-Fc-efficiently binds to gram-negative bacteria. We show in addition that it is the binding pocket formed by TLR4 and MD-2 (16) that detects LPS on the bacterial surface because binding to bacteria was blocked by preincubation of the fusion proteins with LPS and with antibody MTS510, which specifically detects the TLR4/ MD-2 complex.
In gram-negative bacteria, the lipid A moiety of LPS serves as a hydrophobic anchor and forms a lipid bilayer with phospholipids as the inner leaflet (19) . Jain et al. could show that binding of sMD-2 to an LPS-negative mutant of Neisseria meningitidis failed (12) . Since four of the usual six acyl chains of the lipid A moiety are sufficient for the binding to MD-2 (16, 24), Jain et al. conclude that MD-2 binds only to a fraction of the acyl chains while permitting the maintenance of cell wall anchorage (12) . It seems, however, unlikely that-at least in live bacteria-a part of the acyl chains of lipid A could be detected, because they should be masked by the large core-and Ospecific sugar side chains which cover the bacterial surface. We suppose that the polysaccharide chains of dissociated LPS interact with the polysaccharide capsule of live bacteria, thus coating their surface and presenting lipid A for binding with LPS-Trap-Fc.
The opsonization capabilities of sMD-2 and the subsequent enhanced phagocytosis and intracellular killing were shown to be dependent on TLR4 signaling (12) . Since LPS-Trap already consists of the LPS-receptor complex, triggering of TLR4 signaling by our constructs is improbable. LPS-Trap-Fc-coated bacterial particles were phagocytosed with a higher intensity than were their IgG-treated counterparts (Fig. 4A and B) . The phagocytic activity could be modulated by the IgG isotypes of the Fc fusion, while non-Fc chimeras showed no enhancement of phagocytosis (Fig. 4C) . Therefore, the Fc fragments and not the TLR4/MD-2 complex of the bound fusion proteins were responsible for mediating increased phagocytosis. Hence, surface concentrations of fusion proteins on bacteria were sufficient to cross-link the Fc receptors on Mono Mac 6 cells, which is crucial for mediating endocytosis and phagocytosis (8, 29) .
Furthermore, treatment of E. cloacae with LPS-Trap-Fc1 and -Fc3 conferred complement sensitivity on the widely serum-resistant strain (15) (Fig. 5) . These findings corroborate the known biological activities of the different IgG isotypes (5). We conclude, therefore, that the Fc region of the fusion protein can mediate enhanced phagocytosis and complement-mediated killing depending on its isotype, at least in vitro.
In summary, it can be stated that in early gram-negative bacterial bacteremia and sepsis, LPS-Trap-Fc might work by two mechanisms: first, it could trap soluble LPS from host-or antibiotic-killed bacteria, and second, it could opsonize live gram-negative bacteria, rendering them more vulnerable to complement, phagocytosis, and killing by NK cells. In later stages, these molecules might additionally neutralize delayed endogenous mediators of inflammation such as HMGB1 (highmobility group box 1 protein) and thus modulate the inflammatory response in a balanced manner.
